Health

New Drug Approval News: FDA Clears Sunharbo for Stroke

The United States Food and Drug Administration has approved Sunharbo, known by its generic name asundexian, as the first medicine in a new class of blood thinners designed to prevent a second stroke, in the latest new drug approval news to reach American patients this week. The decision, announced on November 9, gives doctors a new option for adults who have just had a mild-to-moderate non-cardioembolic ischaemic stroke or a high-risk transient ischaemic attack, often called a mini-stroke. Sunharbo is made by Bayer HealthCare Pharmaceuticals and is taken as a once-daily 50 mg tablet alongside antiplatelet therapy, the standard blood-thinning treatment after such events.

The approval matters because a second stroke is one of the most feared outcomes in medicine. An ischaemic stroke happens when a clot blocks an artery carrying blood to the brain, and the risk of another one is highest in the days and weeks after the first. Doctors have long relied on antiplatelet drugs such as aspirin and clopidogrel to reduce that danger, but those medicines do not remove the risk entirely, and stronger blood thinners carry a bleeding risk that has limited their use here. Sunharbo is designed to fill that gap by targeting a different part of the clotting system.

The FDA's Hylton Joffe called the approval "a meaningful advance" for secondary stroke prevention, the term doctors use for preventing a repeat event after a first one. The agency granted Sunharbo Fast Track and Priority Review designations, which speed the review of medicines for serious conditions with unmet needs. The approval was based on the OCEANIC-STROKE trial, a large international phase 3 study of 12,327 adults that compared Sunharbo with a placebo, with both groups also receiving antiplatelet therapy. Over a median treatment period of 14.2 months, the risk of ischaemic stroke fell by 26 percent. Bayer has said it expects the medicine to begin shipping in mid-to-late November.

Advertisement

New Drug Approval News: How Sunharbo Works Inside the Body

To understand why Sunharbo has attracted so much attention, it helps to understand how blood clots form. When a blood vessel is injured, the body sets off a chain reaction called the coagulation cascade, a sequence of clotting factors that activate one after another until a fibrin clot seals the wound. Factor XI sits in what doctors call the intrinsic pathway, and its activated form, factor XIa, helps to amplify clot formation. The key insight from years of research is that factor XI appears to matter more for the pathological clots that block arteries in a stroke than for the everyday clotting that stops a cut from bleeding.

Sunharbo is an oral, direct and reversible inhibitor of factor XIa: it binds directly to the activated factor and switches it off, and its effect wears off when the drug leaves the body. That reversibility matters, because the medicine can be paused before surgery and restarted afterwards, and doctors do not need to monitor blood levels as they did with warfarin. It is taken once a day and does not require the regular blood tests and dose adjustments that made warfarin difficult for many patients.

The goal of uncoupling thrombosis from haemostasis has driven anticoagulant research for more than a decade. Existing anticoagulants such as apixaban and rivaroxaban target factor Xa or thrombin, steps further downstream that are more central to normal clotting, which is one reason they carry a meaningful bleeding risk. By moving upstream to factor XIa, researchers hoped to prevent strokes with less disruption to normal clotting, and the trial results suggest that hope was at least partly justified.

Advertisement

The OCEANIC-STROKE Trial: 12,327 Patients, 26 Percent Lower Risk

The evidence behind the approval comes from OCEANIC-STROKE, a phase 3, randomised, double-blind, placebo-controlled trial conducted at centres around the world and presented as a late-breaker at the American Heart Association Scientific Sessions 2026, just days before the FDA acted. The trial enrolled 12,327 adults who had recently had a non-cardioembolic ischaemic stroke, meaning a stroke not caused by a clot travelling from the heart, with a stroke severity score of 15 or lower, or a high-risk transient ischaemic attack with an ABCD2 score of 6 or 7. Patients were randomly assigned within 72 hours of their symptoms starting to receive either asundexian 50 mg once daily or a matching placebo, with both groups continuing their planned single or dual antiplatelet therapy.

The headline result was clear. Ischaemic stroke occurred in 6.2 percent of patients who received Sunharbo, compared with 8.4 percent of those who received placebo, a relative reduction of 26 percent, with a hazard ratio of 0.74. In plain terms, for every hundred patients treated, roughly two fewer suffered a repeat ischaemic stroke. The result was statistically significant, with a p-value of less than 0.0001, and the full results were published in the New England Journal of Medicine in 2026.

The safety results were more nuanced. Major bleeding occurred in 1.9 percent of the Sunharbo group and 1.7 percent of the placebo group, a difference that was not statistically significant. That is reassuring, but experts have noted that the trial was not large enough to rule out a small increase in bleeding risk entirely, and that real-world patients are often older and sicker than trial volunteers. The trial also matters for the class as a whole, because a second factor XIa inhibitor, milvexian from Bristol Myers Squibb and Janssen, is now being tested in its own phase 3 trial, LIBREXIA-STROKE.

Advertisement

Who Can Take Sunharbo, and Who Should Not

The FDA's approval comes with clear boundaries, and understanding them matters for anyone who has had a stroke or cares for someone who has. Sunharbo is approved to reduce the risk of stroke in adults with a recent non-cardioembolic ischaemic stroke, with a stroke severity score of 15 or lower, or a high-risk transient ischaemic attack, in combination with antiplatelet therapy. It is not a treatment for a stroke that is happening now, nor a replacement for the emergency care that a stroke demands. It is a preventive medicine, taken every day, for the months after the event, when the risk of a second stroke is at its highest.

There are also specific limits in the label. Sunharbo is not recommended in patients with moderate or severe hepatic impairment, meaning liver disease that affects how the body processes medicines. It should be withheld for at least 24 hours before elective surgery or an invasive procedure, and for at least 24 hours after thrombolysis, the clot-busting treatment given for an acute ischaemic stroke. It should not be used together with combined P-gp and strong CYP3A4 inducers such as carbamazepine, which can reduce its effectiveness, and it is not approved for stroke prevention in patients with atrial fibrillation, where the separate OCEANIC-AF trial showed it was less effective than apixaban.

For patients, the most practical questions will be about cost, access and whether their own doctor thinks the drug is right for them. Insurance coverage, prior authorisation and patient assistance programmes will shape how quickly Sunharbo reaches the people it is meant to help. Patients outside the trial population should not assume the same benefit applies to them, and any decision to start, stop or change a blood thinner should be made with a doctor, because stopping these medicines suddenly can itself raise the risk of a clot.

Advertisement

A Remarkable Week of FDA Approvals: Imfinzi, Gazyva and Pimjetmi

Sunharbo was not the only significant approval to come out of the FDA in the same week, and the cluster of decisions underlines how busy the agency's autumn has been. On November 13, the FDA approved AstraZeneca's Imfinzi, known generically as durvalumab, in combination with enfortumab vedotin, sold as Padcev, as a treatment before and after surgery for adults with muscle-invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy. The decision was based on the phase 3 VOLGA trial, which enrolled 695 patients at 182 centres in 25 countries, and it showed a 49 percent reduction in the risk of disease progression, recurrence, failure to undergo surgery or death, and a 42 percent reduction in the risk of death, compared with surgery alone.

The same week brought the first drug approved specifically for a rare kidney disease. On November 13, the FDA approved Genentech's Gazyva, known generically as obinutuzumab, for adults with primary membranous nephropathy at risk of disease progression, to induce remission of proteinuria, the leakage of protein into the urine that is a hallmark of kidney damage. The approval rests on the phase 3 MAJESTY trial, which enrolled 142 adults and compared Gazyva with tacrolimus. At week 104, complete remission was achieved in 36 percent of patients given Gazyva, compared with 6 percent of those given tacrolimus. Gazyva was already approved for certain blood cancers and kidney conditions, and its label carries a boxed warning for hepatitis B reactivation and for progressive multifocal leukoencephalopathy, a rare and serious brain infection.

A third approval came on November 10, when the FDA cleared EMD Serono's Pimjetmi, known generically as pimicotinib, for adults with symptomatic tenosynovial giant cell tumour, a rare tumour of the joints and tendon sheaths, where surgery may cause worsening functional limitation or severe morbidity. The dose is 50 mg once daily, and the approval was based on the double-blind MANEUVER trial, in which the objective response rate at week 25 was 56 percent with pimicotinib, compared with 3.2 percent with placebo. Taken together, the four approvals in a single week give doctors in four very different specialties a new option to discuss with their patients before the year is out.

Advertisement

What Happens Next for Stroke Prevention

The immediate next step is availability. Bayer has said Sunharbo will begin shipping in mid-to-late November, so the first prescriptions are likely to be written within weeks rather than months. Doctors, pharmacists and hospital formulary committees will now be working through the practical questions: which patients to prioritise, how to fit the new drug into existing stroke pathways, and how to counsel patients about the balance between a lower risk of another stroke and the small bleeding risk that comes with any blood thinner.

Beyond Sunharbo itself, regulators in Europe and Japan are still reviewing the medicine, and China's National Medical Products Administration already approved it on October 26. The results of the LIBREXIA-STROKE trial of milvexian will show whether the class effect holds, and longer-term safety data from real-world use will matter, because everyday patients will be more varied than the trial population. For stroke survivors, the message is one of cautious optimism: Sunharbo does not remove the risk of a second stroke, but the trial evidence shows it can cut the risk of a repeat ischaemic stroke by about a quarter when added to antiplatelet treatment.

Source: FDA

Advertisement
Advertisement

Leave a Reply

Your email address will not be published. Required fields are marked *

Advertisement
Advertisement
About Us  |  Contact Us  |  Privacy Policy  |  Disclaimer  |  Terms and Conditions